User login
Key clinical point: Initiation of statin treatment within 12 months of diagnosis improves survival in women with stage I-III triple-negative breast cancer (TNBC).
Major finding: Statin treatment was initiated in 2,281 patients within 12 months of diagnosis. In 1,534 patients with TNBC, statin use was associated with a significant improvement in breast cancer-specific survival (standardized hazard ratio [HR], 0.42; P = 0.022) and overall survival (HR, 0.70; P = 0.046). No significant association was observed between statin use and survival in patients without TNBC.
Study details: retrospective study of 23,192 patients with stage I-III breast cancer from the Surveillance, Epidemiology, and End Results-Medicare and Texas Cancer Registry-Medicare database between 2008 and 2015.
Disclosures: The study was supported by National Institutes of Health and Cancer Prevention Research Institute of Texas. The authors received grants, research funding, and personal fees outside this work.
Source: Nowakowska MK et al. Cancer. 2021 Aug 3. doi: 10.1002/cncr.33797.
Key clinical point: Initiation of statin treatment within 12 months of diagnosis improves survival in women with stage I-III triple-negative breast cancer (TNBC).
Major finding: Statin treatment was initiated in 2,281 patients within 12 months of diagnosis. In 1,534 patients with TNBC, statin use was associated with a significant improvement in breast cancer-specific survival (standardized hazard ratio [HR], 0.42; P = 0.022) and overall survival (HR, 0.70; P = 0.046). No significant association was observed between statin use and survival in patients without TNBC.
Study details: retrospective study of 23,192 patients with stage I-III breast cancer from the Surveillance, Epidemiology, and End Results-Medicare and Texas Cancer Registry-Medicare database between 2008 and 2015.
Disclosures: The study was supported by National Institutes of Health and Cancer Prevention Research Institute of Texas. The authors received grants, research funding, and personal fees outside this work.
Source: Nowakowska MK et al. Cancer. 2021 Aug 3. doi: 10.1002/cncr.33797.
Key clinical point: Initiation of statin treatment within 12 months of diagnosis improves survival in women with stage I-III triple-negative breast cancer (TNBC).
Major finding: Statin treatment was initiated in 2,281 patients within 12 months of diagnosis. In 1,534 patients with TNBC, statin use was associated with a significant improvement in breast cancer-specific survival (standardized hazard ratio [HR], 0.42; P = 0.022) and overall survival (HR, 0.70; P = 0.046). No significant association was observed between statin use and survival in patients without TNBC.
Study details: retrospective study of 23,192 patients with stage I-III breast cancer from the Surveillance, Epidemiology, and End Results-Medicare and Texas Cancer Registry-Medicare database between 2008 and 2015.
Disclosures: The study was supported by National Institutes of Health and Cancer Prevention Research Institute of Texas. The authors received grants, research funding, and personal fees outside this work.
Source: Nowakowska MK et al. Cancer. 2021 Aug 3. doi: 10.1002/cncr.33797.